Viridian Therapeutics, Inc. (LON:0K1R)
London
· Delayed Price · Currency is GBP · Price in USD | Market Cap | 1.02B |
| Revenue (ttm) | 225.32K |
| Net Income (ttm) | -191.81M |
| Shares Out | n/a |
| EPS (ttm) | -3.18 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 112 |
| Average Volume | 724 |
| Open | 16.81 |
| Previous Close | 16.52 |
| Day's Range | 16.69 - 16.90 |
| 52-Week Range | 10.98 - 29.30 |
| Beta | 1.35 |
| RSI | 39.62 |
| Earnings Date | Feb 27, 2025 |
About Viridian Therapeutics
Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company’s product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune dise... [Read more]
Financial Performance
In 2023, Viridian Therapeutics's revenue was $314,000, a decrease of -82.28% compared to the previous year's $1.77 million. Losses were -$237.73 million, 83.0% more than in 2022.
Financial numbers in USD Financial StatementsNews
Viridian Therapeutics Announces Inducement Grants for New Employees
Viridian Therapeutics Announces Inducement Grants for New Employees
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare di...
Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseas...
Viridian: Positive Chronic TED Data Likely To Lead To BLA Filing In Second Half Of 2025 (Rating Upgrade)
Viridian Therapeutics advances promising therapies for thyroid eye disease. See why VRDN stock stands to benefit from a growing $4.13B market by 2034.
Viridian Therapeutics: Veligrotug De-Risked In TED With Hints Of Differentiation
Viridian's veligrotug shows promising results in treating TED patients, setting the stage for future growth in the biopharmaceutical company. Read more here.
Viridian Therapeutics: A Clearer Picture Emerges (Rating Upgrade)
Viridian Therapeutics, Inc.'s stock soars on positive trial results, analysts bullish on FDA approval in 2026. Read more on VRDN stock prospects.
Tesla, Micron, Broadcom, MARA Holdings And Other Big Stocks Moving Higher On Monday
U.S. stocks were mostly higher, with the Nasdaq Composite gaining around 1% on Monday. Shares of Tesla, Inc. (NASDAQ: TSLA) rose sharply during Monday's session after Wedbush maintained an Outperform...
Viridian stock soars 25% on Phase 3 data for veligrotug
Viridian (VRDN) shares shot up 25% after the company reported positive results from a Phase 3 study of veligrotug in the treatment of chronic thyroid eye disease. Read more here.
Viridian Therapeutics Skyrockets After Besting Amgen In Thyroid Eye Disease
Viridian Therapeutics stock popped Monday after the company scored a win in thyroid eye disease, a condition that causes the eyes to swell.
Viridian Therapeutics Announces Positive Phase 3 Results for Veligrotug in Treating Thyroid Eye ...
Viridian Therapeutics Announces Positive Phase 3 Results for Veligrotug in Treating Thyroid Eye Disease
Viridian Therapeutics' eye disorder drug meets late-stage study goal
Viridian Therapeutics said on Monday its experimental drug to treat an immune system disorder, chronic thyroid eye disease, met the main goal of a late-stage study.
Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare di...
Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare di...
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare di...
Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseas...
Viridian Therapeutics' Superior Prospects Make It A Buy
Viridian Therapeutics, Inc.'s VRDN-001, now Veligrotug, shows promising phase 3 data in Thyroid Eye Disease, outperforming Tepezza in early stages and targeting both active and chronic TED. VRDN-001 a...
3 Small Biotech Stocks With The 'Big Mo' Right Now
Three small biotech stocks that I have covered lately have shown significant upward movement recently due to positive news. The stocks are experiencing what I call the 'Big Mo,' indicating strong mome...
Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseas...
Viridian: Active TED Data Signifies Next Round Of Positive Data On The Way
Viridian Therapeutics, Inc. reported that the primary endpoint was met for the phase 3 THRIVE study, using veligrotug for the treatment of patients with active thyroid eye disease. Data release for TH...
Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseas...
Viridian Therapeutics' eye disorder treatment meets main goal in late-stage study
Viridian Therapeutics said on Tuesday its experimental drug to treat patients with thyroid eye disease significantly reduced bulging of the eye in a late-stage study.
Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare di...
Viridian Therapeutics to Webcast VRDN-001 Phase 3 THRIVE Topline Results on September 10, 2024
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare di...
Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2024 Financial Results
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseas...
Top 3 Health Care Stocks You May Want To Dump This Quarter
As of July 30, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.